Fig. 5

MT1H suppresses tumorigenicity in vivo. a Tumor growth curves measured after subcutaneous injection of HepG2-Vector and HepG2-MT1H. The tumor volume was calculated every 5 days. Error bars indicate standard deviation (Student’s t-test; *, P < 0.05, n = 5). b Photographs of dissected tumors from nude mice. c Weight of tumors from mice with HepG2-Vector or HepG2-MT1H implantation. Error bars indicate standard deviation (Student’s t-test; *, P < 0.05, n = 5)